anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To propose a technology allowing high-accuracy specification of erroneous notation inside an electronic document (text) and corresponding right notation even in a field (e.g. a medical field) wherein a morpheme-analyzing dictionary is not completed and sufficient morpheme analysis accuracy is impossible to obtain.  <P>SOLUTION: Based on processing results of a morpheme analysis means 2 and a word likelihood calculation means 3, an erroneous notation correction candidate specification means by preparer 4 extracts a character string having low appearance probability only inside a report written by a specific doctor as a candidate of the right notation. An erroneous notation correction means by preparer 6 extracts a character string having high appearance probability only inside a report written by a specific doctor as a candidate of the erroneous notation to the respective obtained character strings. Similarity is calculated to all combinations of the respective character strings by a word similarity calculation means 5, and the erroneous notation correction means 6 specifies a combination having high similarity as an erroneous notation word and its correction word.  <P>COPYRIGHT: (C)2009,JPO&INPIT
In a first aspect, the present invention provides compositions for treating burns. The compositions, containing effective amounts of a processed  Morinda citrifolia  product may be used to stimulate, expedite or assist in healing the burned skin of patients. The processed  Morinda citrifolia  product may be a fruit juice, a puree juice, a fruit or puree juice concentrate, an oil extract, dietary fiber, or an alcohol or aqueous extract. The compositions may be formulated into creams, lotions, gels, aerosols and the like. Other optional ingredients may be added including, for instance, fillers, emulsifiers, thickeners, emollients, fragrances and dyes. The present invention further provides a method for treating a burn injury by administering a topical composition comprising at least one processed  Morinda citrifolia  product.
Breast biopsies for patients with abnormal mammograms are required to identify cancerous tissue. Currently this procedure is done with or without a local anesthetic. Patients report anxiety regarding potentially having cancer and the possibility of cancer-related procedures. Different types of biopsies may have different pain and anxiety based on their duration and complexity. This research is designed to determine if VR simulated environment can reduce pain and anxiety.

The aim is to study the efficacy of a virtual environment in reducing pain and procedural anxiety. It is intended for patients undergoing an ultrasound guided breast biopsy procedure that have had an abnormal mammogram. The overall aim is to discover an efficacious nonpharmacologic method to lower pain and anxiety during a standard of care procedure.
1,263,026. 9,10-Dihydro-9,10-ethano-9-anthroylalkylamine derivatives. CIBA-GEIGY A.G. 11 May, 1970 [10 May, 1969; 2 April, 1970], No. 22660/70. Heading C2C. Novel compounds of Formula I wherein R 1  and R 2  are each H, Cl or C 1-6  alkoxy, R 4  and R 5  are each H, halogen, OH, CF 3 , C 1-6  alkyl or C 1-6  alkoxy and "alk" is a divalent saturated aliphatic hydrocarbon radical are prepared by one of the following methods: (a) reduction of the C=N bond in compounds of Formula V where X is a radical of Formula VIa or VIb where alk q H is alk; (b) reduction of keto group to methylene in a compound of Formula VIc wherein alk b -CH 2 - is alk; (c) hydrolysis of the acyl radical Y in a compound of Formula VII (d) reaction of a compound of Formula VIIIa with a compound of Formula VIIIb wherein one of Z 1  and Z 2  is amino and the other is a reactive esterified hydroxyl group; (e) reaction of a compound of Formula IX with a compound of Formula X under catalytic reducing conditions; or (f) reacting a compound of Formula XI with a compound of Formula XII under catalytic reducing conditions; and, if desired, in all cases converting any substituent in a product into another desired substituent by known methods and/or resolving any optical antipodes. Intermediates of Formula VIc above are prepared by reaction of the appropriate acid chloride and amine.  9 - [(α - methyl - phenethylimino)methyl [ - 9,10- dihydro-9,10-ethanoanthracene is prepared by reaction of α-methylphenethylamine and the appropriate aldehyde. Pharmaceutical compositions in conventional forms for enteral or parenteral administration and having use as agents for treating angina pectoris comprise an above novel compound and a carrier or diluent.
Automatic pain assessment is an application in healthcare serving personalized pain care, and patients cannot self-report pain. Pain at the present is inferred from physiological dynamics at the present and in the near past. However, heterogeneous pain responses cross-subject and cross-type hinder accurate recognition of pain. This work solves the adaptive pain recognition problem across pain types. We concrete the adaptivity problem into recognizing both phasic/short and tonic/long pain from the physiological sequences of the same length. The adaptivity of the proposed solution (TCAtt-PainNet) was ensured by hybrid temporal-channel attention when fusing multivariate time-series of electrocardiogram (ECG) and galvanic skin response (GSR) features. The attention was obtained by learning the dependencies between the point at present and the sequence in the near past, where sequence point temporal attention was constructed via modified self-attention, and the following feature channel attention was constructed by squeeze-and-excitation temporal attention weighted deep feature sequence. The proposed solution successfully enhanced recognition adaptivity by addressing relevant information only from long input sequences when testing with tonic and phasic pain databases, making progress towards automatic pain assessment for real application scenarios with attributes unknown pain.
Neutrophil-to-lymphocyte ratio (NLR), calculated from peripheral blood immune-inflammatory cell counts, is considered a predictor of survival in various cancers. Nevertheless, there is a lack of research into the predictive value of NLR specifically in gastric cancer patients following surgery using the Da Vinci robot. Investigate the objectives of this research, confirm the positive predictive value of NLR in the prognosis of gastric cancer patients undergoing Da Vinci robotic-assisted surgery by comparing its prognostic ability with other inflammation markers and tumor biomarkers. In this retrospective analysis, information from 128 individuals diagnosed with gastric cancer and treated with da Vinci robot-assisted surgery was examined. The study examined various markers in the peripheral blood, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), systemic immune-inflammatory index (SII) prognostic nutrition index (PNI), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4), carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP).To ascertain the prognostic ability and optimal cutoff values of each parameter, operating characteristic curves and the area under the curve were utilized in the analysis. For evaluation of independent prognostic factors, we utilized Kaplan-Meier curves and multifactorial Cox analysis. The variables from the multifactorial Cox analysis were used to construct a nomogram. NLR, LMR, CEA, AFP, primary location, largest tumor size and TNM stage were all found to be significant predictive elements for overall survival (OS). Multivariate Cox identified NLR (P = 0.005), LMR (P = 0.03) and AFP (P = 0.007) as the only separate predictive variables among hematological indicators. The nomogram built using NLR demonstrates excellent predictive performance at 1 year (AUC = 0.778), 3 years (AUC = 0.773), and 5 years (AUC = 0.781). Cross-validation demonstrates that this model has favorable predictive performance and discriminative ability. NLR is an uncomplicated yet potent marker for forecasting the survival result of individuals with gastric cancer following da Vinci robotic surgery, and it possesses considerable predictive significance. The nomogram based on NLR provides patients with a visual and accurate prognosis prediction.
Participants receive boserolimab at the selected dose via IV infusion PLUS pembrolizumab via IV infusion PLUS nab-paclitaxel 100 mg/m\^2 via IV infusion. Boserolimab and pembrolizumab will be given on Day 1 of each 6-week cycle (Q6W). Nab-paclitaxel will be given on a 3-week on (Days 1, 8 and 15)/ 1-week off schedule every 28 days. Boserolimab and pembrolizumab will be given for up to a total of 18 cycles (approximately 2 years).
Individual coaching with a trained patient experience professional (XTEC coach) will occur individually with clinicians 3-4 times over several weeks. The coach will assist participants with improving communication with patients.
Postpartum hemorrhage (PPH) is one of the leading causes of death during childbirth and accounts for an estimated 140,000 deaths per year worldwide. The World Health Organization (WHO) recommends active management of the third stage of labor to prevent PPH, even in low risk patients. Prophylactic uterotonic drugs administered after delivery are the main element of active management of the third stage and have been demonstrated to reduce the incidence of PPH by up to 40%.

Oxytocin is the most commonly used uterotonic in North America, however it has a very short duration of action and requires a continuous infusion to achieve sustained effect, with large doses associated with adverse effects like low blood pressure, nausea, vomiting, abnormal heart rhythms and changes on ECG. Carbetocin is a synthetic oxytocin analogue. It causes uterine contraction via the same mechanism as oxytocin. Its duration of action is 4 to 7 times that of oxytocin due to an increased biological half-life in plasma and at the oxytocin receptors in the uterus. The Society of Obstetricians and Gynecologists of Canada (SOGC) has recommended a single dose of 100 mcg of carbetocin at elective cesarean delivery to promote uterine contraction. In a study performed at Mount Sinai Hospital, the investigators have shown that smaller doses of carbetocin (14.8 mcg) are effective in achieving adequate uterine tone at elective cesarean section. However this study was limited to those women with a BMI of \<40 kg/m2

The prevalence of obesity is increasing in young women and some studies have shown that obese women have higher rates of caesarean delivery compared to non-obese women. Other studies have demonstrated an increased risk of hemorrhage due to poor uterine tone in obese women. Laboratory studies show that BMI alone appears to contribute to blunted uterine muscle responses and therefore contraction responses to oxytocin in obese women. Previous dose finding studies have excluded those women with a BMI of ≥40kgm2. Therefore, the investigators wish to perform a double-blind dose finding study using the biased coin up-and-down sequential allocation technique to determine the ED90 of carbetocin at caesarean section in those women with a BMI\>40.
The invention relates to a blood circulation-promoting and pain-stopping medicament for treating chest stuffiness and pains. The medicament consists of the following bulk pharmaceuticals in parts by weight: 12-18 parts of Chinese angelica, 12-18 parts of rehmannia root, 6-10 parts of officinal magnolia bark, 6-10 parts of cassia twig, 8-12 parts of szechuan lovage rhizome, 12-18 parts of tree peony root-bark, 8-12 parts of sargentg loryvine stem, 8-12 parts of corydalis tuber, 8-12 parts of safflower, 6-10 parts of immature bitter orange, 8-12 parts of red paeony root, 8-12 parts of fortune's drynaria rhizome and 3-5 parts of borneol. A preparation process of the medicament comprises the following steps of: smashing 3-5 parts by weight of borneol into fine powder of 120-150 meshes; smashing other medicinal materials except borneol into fine powder of 20-40 meshes, and performing ethanol extraction to obtain ethanol extract fine powder; and uniformly mixing the products. After the medicinal materials are used together, the effects of promoting blood circulation, removing blood stasis, promoting qi circulation and relieving pain are achieved. The medicament is used for treating symptoms such as chest stuffiness and pains and the like caused by blood stasis in chest and obstruction of the blood circulation. The total effective rate is 90.3 percent.
Wnt-5a is a protein encoded by the WNT5A gene and is a ligand for the receptor tyrosine kinase-like orphan receptor 2 (ROR2). However, its biological impact on clear cell renal cell carcinoma (ccRCC) remains unclear. In this study, the prognostic significance of concurrent WNT5A and ROR2 expression levels was observed to predict unfavorable overall survival and disease-specific survival. High Wnt-5a expression was detected in a ccRCC cell line panel but not in HK-2 cells, a normal proximal tubular cell line. Inhibition of DNA methyltransferase by 5-azacytidine in 786-O and Caki-2 cells resulted in Wnt-5a up-regulation, indicating potential epigenetic modification. Furthermore, there was a repression of cell movement in vitro and metastatic colonization in vivo on WNT5A and ROR2 knockdown. Suppressions of angiogenesis in vivo and tubular-like structure formation in endothelial cells in vitro were also observed after silencing WNT5A and ROR2 expression. In addition, alteration in the downstream gene signature of the Wnt-5a-ROR2 signaling was similar to that in metastasis-associated gene 1-β-catenin axis. Moreover, prunetin treatment reversed the gene signature derived from Wnt-5a-ROR2 signaling activation and to abolish ccRCC cell migration and proliferation. Overall, this study demonstrates the clinical and functional significance of the Wnt-5a-ROR2 axis and identifies prunetin as a potential precision medicine for patients with ccRCC harboring aberrant Wnt-5a-ROR2 signaling pathways.
Study M03-658 was a continuation study for participants with moderate to severe psoriasis who had participated in a prior psoriasis adalimumab study. Study M03-658 consisted of three sequential treatment periods. The first period was Period O, in which participants received open-label treatment with adalimumab (40 mg every other week or 40 mg every week) for a minimum of 104 weeks and a maximum of 252 weeks. Period O was the only period of the study until May 2008, when the subsequent periods were added via amendment to the protocol. At that time, participants who had achieved satisfactory therapeutic response (a Physician's Global Assessment \[PGA\] of 0, 1, or 2 \[clear, minimal, or mild\]) were given the opportunity to discontinue from the study or to continue and participate in the subsequent two periods. The second period was Period W, a maximum of 52 weeks, in which participants with a PGA of 2 (mild) or less were withdrawn from adalimumab treatment (i.e., participants received no treatment) until relapse of their psoriasis occurred (defined as a PGA of 3 \[moderate\] or worse). The third period was Period R, a 16-week period in which participants were retreated with open-label adalimumab (80 mg initial dose followed by 40 mg every other week). Period O was designed to evaluate the first objective regarding long-term efficacy and safety of adalimumab treatment, and Period R was designed to evaluate the effectiveness of adalimumab retreatment following relapse. Specific subsets of the study population that were identified as the populations of interest were the modified intent-to-treat populations for Period W and Period R, and these are described further in the outcome measures.
Perfluoroalkyl acids (PFAAs) of different chemical speciation were previously found to cause diverse toxicity. However, the toxicological mechanisms depending on chemical speciation are still largely unknown. In this follow-up study, zebrafish embryos were acutely exposed to only one concentration at 4.67 μM of the acid and salt of representative PFAAs, including perfluorooctanoic acid (PFOA), perfluorobutane carboxylic acid (PFBA), and perfluorobutanesulfonic acid (PFBS), till 96 h post-fertilization (hpf), aiming to gain more mechanistic insights. High-throughput proteomics found that PFAA acid and salt exerted discriminative effects on protein expression pattern. Bioinformatic analyses based on differentially expressed proteins underlined the developmental cardiotoxicity of PFOA acid with regard to cardiac muscle contraction, vascular smooth muscle contraction, adrenergic signaling in cardiomyocytes, and multiple terms related to myocardial contraction. PFOA salt and PFBS acid merely disrupted the cardiac muscle contraction pathway, while cardiac muscle cell differentiation was significantly enriched in PFBA acid-exposed zebrafish larvae. Consistently, under PFAA exposure, especially PFOA and PFBS acid forms, transcriptional levels of key genes for cardiogenesis and the concentrations of troponin and epinephrine associated with myocardial contraction were significantly dysregulated. Moreover, a transgenic line Tg (my17: GFP) expressing green fluorescent protein in myocardial cells was employed to visualize the histopathology of developing heart. PFOA acid concurrently caused multiple deficits in heart morphogenesis and function, which were characterized by the significant increase in sinus venosus and bulbus arteriosus distance (SV-BA distance), the induction of pericardial edema, and the decrease in heart rate, further confirming the stronger toxicity of PFOA acid than the salt counterpart on heart development. Overall, this study highlighted the developmental cardiotoxicity of PFAAs, with potency ranking PFOA > PFBS > PFBA. The acid forms of PFAAs induced stronger cardiac toxicity than their salt counterparts, providing an additional insight into the structure-toxicity relationship.
Global cerebral ischemia (GCI) caused by clinical conditions such as cardiac arrest leads to delayed neuronal death in the hippocampus, resulting in physical and mental disability. However, the mechanism of delayed neuronal death following GCI remains unclear. To elucidate the mechanism, we performed a metabolome analysis using a mouse model in which hypothermia (HT) during GCI, which was induced by the transient occlusion of the bilateral common carotid arteries, markedly suppressed the development of delayed neuronal death in the hippocampus after reperfusion. Fifteen metabolites whose levels were significantly changed by GCI and 12 metabolites whose levels were significantly changed by HT were identified. Furthermore, the metabolites common for both changes were narrowed down to two, adenosine monophosphate (AMP) and xanthosine monophosphate (XMP). The levels of both AMP and XMP were found to be decreased by GCI, but increased by HT, thereby preventing their decrease. In contrast, the levels of adenosine, inosine, hypoxanthine, xanthine, and guanosine, the downstream metabolites of AMP and XMP, were increased by GCI, but were not affected by HT. Our results may provide a clue to understanding the mechanism by which HT during GCI suppresses the development of delayed neuronal death in the hippocampus.
First, the intervention group 2 completed the pretest knowledge, attitude, and behavior questionnaire. Then, illustrated booklet was made available to this group. The questionnaire was completed again by the group one week after completion of training, and then one month afterward.
BACKGROUND: Approximately 10% of intraoperative cholangiograms identify choledocholithiasis (CDL), stones in the common bile duct. Choledocholithiasis management options include endoscopic retrograde cholangiopancreatography (ERCP) followed by cholecystectomy, laparoscopic cholecystectomy (LC) followed by ERCP (LC + ERCP), cholecystectomy with open common bile duct exploration, or laparoscopic cholecystectomy with laparoscopic common bile duct exploration (LC + LCBDE). The goal of these interventions is to clear the obstruction from CDL.
METHODS: Patients from a single-center community hospital undergoing LC with intraoperative cholangiogram (LC + IOC) progressing to LC + LCBDE from July 2020 to August 2022 were evaluated for hospital length of stay (LOS), operative times, and complications. These were compared to the prior standard practice of pre/post-operative ERCP.
RESULTS: The results were evaluated using ANOVA, Student-Newman-Keuls, and chi square analysis. In comparison of LC + CBDE to ERCP + cholecystectomy, LOS was reduced (1.8 vs 4.6 days P < .0001). No difference in LOS between LC + IOC and LC + CBDE (1.4 vs 1.8 days, P > .05) was found. No difference in complication rates was found. Mean operative time differed between LC + IOC and LC + CBDE (63 vs 113 minutes, P < .0001). Fifty-five attempts of LC + CBDE were performed with only 10 requiring post-operative ERCP.
DISCUSSION: Since implementation of LC + CBDE, there has been reduced LOS without increasing complication rates. Operative times are increased with LC + CBDE but offset by reduced LOS, additional anesthesia events, and procedures. Our institution will continue to pursue LC + CBDE when indicated with efforts to improve resource allocation.
FIELD: medicine.SUBSTANCE: invention may be used to diagnose an oesophageal neoplasm expansion by magnetic resonant tomography (MRT). Integrated MRT is performed before treatment and during controlling the results of chemo- and/or radiation therapy. The study is three-staged. The first stage involves forming high-resolution T2-weighted images in axial and sagittal planes with using a pulse sequence of fast spin-echo with the following parameters: field of view (FOV) 32, slice thickness 4.0, train repetition (TR) period 675, echo signal time (TE) 100, array of frequency and phase 384 and 256 respectively, echo train length (etl) 23, number of excitations (NEX) in the layer selected 4. The formed images are used to talk about the neoplasm expansion, oesophageal layers differentiation, their relation to surrounding organs and tissues, as well as on the presence of metastatic changes and doubtful sites of metastatic involvement to be visualised by means of the second stage of MRT. To this effect, at the second stage diffuse weighted images (DWIs) are formed in the axial plane with the following pulse train parameters: B-value 800, field of view 36, slice thickness 5.0, train repetition (TR) period 8,000, minimum (min) echo signal time (TE), array of frequency and phase 128 and 192 respectively, number of excitations (NEX) in the layer selected 16. Doubtful and metastatic sites are visualised on the T2-weighted images by mapping the formed DWIs onto the T2-weighted images. The third stage involves forming T1-weighted images in the signal suppression mode from fatty tissue before and after administering a gadolinium-containing contrast medium, with using a fast clear gradient-induced echo train with the following parameters: field of view (FOV) 32, slice thickness 4.0, train repetition (TR) period 370, minimum (min) echo signal time (TE), Flip angle 80, array of frequency and phase 384 and 384 respectively, echo train length (etl) 23, number of excitations (NEX) in the layer selected 2. A degree of contrast medium accumulation shows a degree of tissue involvement into the neoplasm.EFFECT: more informative diagnosing of this pathology by using an integrated approach to the examination, improving MRT visualisation characteristics, and optimising examination parameters.2 ex